Navigation Links
Biocept, Inc. Announces New CFO
Date:7/15/2011

SAN DIEGO, July 15, 2011 /PRNewswire/ -- Biocept, Inc. announced today that it has appointed William G. Kachioff as Senior Vice President, Finance and Chief Financial Officer.  As CFO, Mr. Kachioff will be responsible for management of the company's accounting, finance, treasury, investor relations, risk management and information systems functions. Kachioff has more than 20 years of leadership experience in helping to build life science companies. Prior to joining Biocept, Kachioff was CFO at Althea Technologies, a contract manufacturer of pharmaceuticals.

A graduate of the State University of New York at Buffalo, Kachioff began his career as a certified public accountant with Deloitte & Touche LLP in Rochester, NY and Chicago.  Mr. Kachioff has held financial management positions in a wide variety of private and public life science companies, including Abbott Laboratories, Clarient, Inc. (a GE Healthcare Company), Vivus, Inc. and Cutera, Inc., where his responsibilities have included oversight of accounting, compliance, investor relations, financial planning, information systems, logistics and capital formation.

David F. Hale, Executive Chairman of Biocept, commented, "Bill's proven leadership in helping manage life science companies through their initial product commercialization phase will be invaluable to Biocept as we bring OncoCEE-BR™ for breast cancer, the company's first clinical laboratory services product for circulating tumor cell analysis, to market. We are delighted to have Bill join our highly experienced management team."  Hale continued," We believe that Biocept will benefit from Bill's proven track record and his exemplary combination of business judgment, professional skills and integrity."

About Biocept, Inc.

Biocept Laboratories, headquartered in San Diego, California, is an advanced CLIA-certified laboratory services company specializing in the capture, detection, enumeration and analysis of circulating tumor cells (CTCs). Biocept's mission is to enhance the lives of cancer patients through the development of innovative diagnostic products and services. Biocept utilizes innovative, proprietary technologies to deliver clinically relevant and actionable information to physicians that enable better patient care. This includes clinical assessments of CTCs, both prognostic and predictive, which may provide physicians with information highly relevant for the treatment of their patients with cancer.

About OncoCEE™

The OncoCEE™ platform, developed by Biocept, has demonstrated that it can consistently and accurately capture extremely rare cells, like CTCs, which may be present in only 1 of every 50-100 billion blood cells.  Biocept obtains patient samples via a simple blood draw, or "liquid biopsy", instead of relying on traditional biopsy methods or surgical procedures.  Biocept differentiates its "liquid biopsy" CTC analysis by combining enhanced prognostic (CTC enumeration) and predictive (e.g., HER2 status) biomarker analyses, information not currently available through commercial laboratories using existing technologies for CTC testing.  Other methods to capture, detect and enumerate CTCs rely only on the expression of epithelial cell adhesion molecule (EpCAM) and cytokeratins, and do not include molecular biomarker analysis.  This approach may exclude CTCs that have undergone intrinsic modifications of their phenotype, such as the epithelial-to-mesenchymal transition (EMT).  EMT may represent a possible explanation for many patients who, despite having aggressive disease, are found negative for the presence of CTCs. OncoCEE™ has the potential to capture not only epithelial (i.e., EpCAM positive) but also mesenchymal-like CTCs.  Additionally, the OncoCEE™ platform enables evaluation of predictive biomarkers by techniques like immunocytochemistry, fluorescence in situ hybridization (FISH) and mutation analysis.  An example is HER2 status, which Biocept determines by FISH. HER2 status is predictive of a potential response to HER2- targeted agents such as Herceptin® and Tykerb®.

For more information, please contact Michael Dunn, Sr. VP, Corporate Development at 888-332-7729 or by visiting Biocept's web site at http://www.biocept.com . The Company's website is not part of this press release.


'/>"/>
SOURCE Biocept, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Biocept, Inc. Announces CEO and Director Appointments
2. Biocept, Inc. Announces Two New Director Appointments
3. Biocept, Inc. Announces New Director Appointment - September 28, 2010
4. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
5. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
6. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
7. Anesiva Announces Second Quarter 2008 Financial Results and Update
8. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
9. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
10. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
11. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... ... April 26, 2016 , ... ... that Ardy Arianpour has joined the company as Chief Business Officer. Arianpour, a ... innovative genomic technologies to market, was most recently Chief Commercial Officer of Pathway ...
(Date:4/26/2016)... ... April 26, 2016 , ... Heidelberg ... the latest technology innovation for its Volume Pattern Generator (VPG) line of lithography ... of advanced photomasks as well as a solution for mid volume direct write ...
(Date:4/26/2016)... ... April 26, 2016 , ... This unique "Fertility Happy Hour" event will be ... opportunity to get the lowdown on female fertility and the reproductive technologies that are ... Hade, of Boston IVF - The Arizona Center, will give a short presentation and ...
(Date:4/26/2016)... ... April 26, 2016 , ... Seattle ... significant operating grant from 1Plus12 Corporation. The grant will be used to further ... outlined on the organization's website http://www.ivsci.org , In accounting the grant ...
Breaking Biology Technology:
(Date:3/17/2016)... ABI Research, the leader in transformative ... market will reach more than $30 billion by ... Consumer electronics, particularly smartphones, continue to boost the ... reach two billion shipments by 2021 at a ... Research Analyst at ABI Research. "Surveillance is also ...
(Date:3/14/2016)... , Allemagne, March 14, 2016 ... ) - --> - Renvoi : image ... --> --> ... biométriques, fournit de nouveaux lecteurs d,empreintes digitales pour ... de DERMALOG sera utilisé pour produire des cartes ...
(Date:3/10/2016)... , March 10, 2016   Unisys Corporation (NYSE: ... Border Protection (CBP) is testing its biometric identity solution ... Diego to help identify certain non-U.S. citizens leaving ... The test, designed to help determine the efficiency and accuracy ... in February and will run until May 2016. --> ...
Breaking Biology News(10 mins):